Durvalumab with chemoradiotherapy for limited-stage small-cell lung cancer.

[1]  K. Nackaerts,et al.  Consolidation nivolumab and ipilimumab versus observation in limited-disease small cell lung cancer after chemo-radiotherapy - Results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  H. Pyo,et al.  Clinical Outcomes of Pencil Beam Scanning Proton Therapy in Locally Advanced Non-Small Cell Lung Cancer: Propensity Score Analysis , 2021, Cancers.

[3]  C. Rudin,et al.  Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  S. Gettinger,et al.  Second-Line Nivolumab in Relapsed Small-Cell Lung Cancer: CheckMate 331. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  N. Reinmuth,et al.  Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133) , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  W. Curran,et al.  Patterns of Disease Progression after Carboplatin/Etoposide + Atezolizumab in Extensive-Stage Small-Cell Lung Cancer (ES-SCLC). , 2020, International journal of radiation oncology, biology, physics.

[7]  Y. Bang,et al.  Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. , 2020, The Lancet. Oncology.

[8]  Joe Y. Chang,et al.  Phase I/II Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage Small Cell Lung Cancer. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[9]  N. Reinmuth,et al.  LBA86 Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN , 2020 .

[10]  C. Rudin,et al.  Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Steven H. Lin,et al.  Rates of Overall Survival and Intracranial Control in the Magnetic Resonance Imaging Era for Patients With Limited-Stage Small Cell Lung Cancer With and Without Prophylactic Cranial Irradiation , 2020, JAMA network open.

[12]  D. Planchard,et al.  Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic Small-Cell Lung Cancer: Results From the KEYNOTE-028 and KEYNOTE-158 Studies. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[13]  Young Hak Kim,et al.  Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial , 2019, The Lancet.

[14]  N. Reinmuth,et al.  PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN , 2019, Annals of Oncology.

[15]  A. Dingemans,et al.  Current management of limited-stage SCLC and CONVERT trial impact: Results of the EORTC Lung Cancer Group survey. , 2019, Lung cancer.

[16]  Charles R. Thomas,et al.  Radiation Dose and Fractionation for Limited‐stage Small‐cell Lung Cancer: Survey of US Radiation Oncologists on Practice Patterns , 2019, Clinical lung cancer.

[17]  Young Suk Kim,et al.  Dummy Run of Quality Assurance Program before Prospective Study of Hippocampus-Sparing Whole-Brain Radiotherapy and Simultaneous Integrated Boost for Multiple Brain Metastases from Non-small Cell Lung Cancer: Korean Radiation Oncology Group (KROG) 17-06 Study , 2018, Cancer research and treatment : official journal of Korean Cancer Association.

[18]  A. Mansfield,et al.  First‐Line Atezolizumab plus Chemotherapy in Extensive‐Stage Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[19]  D. Planchard,et al.  Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC , 2018, The New England journal of medicine.

[20]  H. Shih,et al.  Safety of Combined PD‐1 Pathway Inhibition and Intracranial Radiation Therapy in Non–Small Cell Lung Cancer , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[21]  A. Bezjak,et al.  Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial , 2017, The Lancet. Oncology.

[22]  T. Yamanaka,et al.  Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. , 2017, The Lancet. Oncology.

[23]  Heung Tae Kim,et al.  Effect of Accurate Staging Using Positron Emission Tomography on the Outcomes of Prophylactic Cranial Irradiation in Patients With Limited Stage Small‐Cell Lung Cancer , 2017, Clinical lung cancer.

[24]  E. Lipson,et al.  Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer. , 2016, JAMA neurology.

[25]  A. Vortmeyer,et al.  Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. , 2016, The Lancet. Oncology.

[26]  M. Ahn,et al.  Phase III trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small-cell lung cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  John Wong,et al.  Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. , 2013, International journal of radiation oncology, biology, physics.

[28]  R. Komaki,et al.  Clinical Investigation : Thoracic Cancer Penetration of Recommended Procedures for Lung Cancer Staging and Management in the United States Over 10 Years : A Quality Research in Radiation Oncology Survey , 2013 .

[29]  L. Collette,et al.  Prophylactic cranial irradiation in extensive small-cell lung cancer. , 2007, The New England journal of medicine.

[30]  R. Komaki,et al.  Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. , 1999, The New England journal of medicine.